Toothpaste Bebble, for children, from 6 months, with strawberry aroma, 50 ml

Be the first to review this product

Special Price $9.80 Regular Price $17.00

In stock

SKU

OTC1020868

Volume, ml

fifty

Brand name

Bebble

Scope of use

Oral cavity

Act

Enamel strengthening

The target audience

Children

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Details

Description

Release form

Powder for oral solution

pharmachologic effect

Combined drug, the action of which is due to the composition of its components.

Paracetamol has analgesic and antipyretic effects.

Guaifenesin has a mucolytic effect, facilitates the removal of phlegm from the bronchi and promotes the transition of an unproductive cough to a productive one.

Phenylephrine is a sympathomimetic, has a pronounced alpha-adrenergic activity, narrows the vessels of the nasal mucosa, eliminates swelling and hyperemia of the nasal mucosa.

Pharmacokinetics

Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract.

After oral administration, Cmax of paracetamol in plasma is reached after 10-60 minutes.

It is metabolized in the liver and excreted in the urine, mainly in the form of glucuronides and sulfate compounds.

T1 / 2 is 1-3 hours.

Guaifenesin is rapidly absorbed from the gastrointestinal tract (25-30 minutes after ingestion).

T1 / 2 - 1 hour. Metabolized in the liver by oxidation to β - (2-methoxy-phenoxy) -lactic acid, which is excreted in sputum and kidneys in the form of inactive metabolites.

Phenylephrine has an irregular absorption from the gastrointestinal tract and at the first stage of metabolism is exposed to monoamine oxidase in the intestine and liver, therefore, oral administration of phenylephrine reduces its bioavailability.

It is excreted in the urine in the form of sulfate compounds.

Cmax in plasma is achieved after 1-2 hours, T1 / 2 is 2-3 hours.

Indications

Symptoms of colds and flu (headache, sore throat, pain in the body and limbs, nasal congestion, cough with difficult discharge of viscous sputum, fever).

Contraindications

Liver dysfunction severe chronic renal failure arterial hypertension hyperthyroidism diabetes phenylketonuria IHD (acute myocardial infarction, atherosclerosis of the coronary arteries) aortic stenosis tachyarrhythmia peptic ulcer of the stomach and duodenum in the acute stage hyperplasia of the prostate angle-closure glaucoma porphyria pheochromocytoma age up to 12 years burden, lactation period simultaneous administration of beta-blockers, tricyclic antidepressants, MAO inhibitors (including within 14 days after their cancellation) concomitant use of other sympathomimetic drugs concomitant use of other drugs containing paracetamol sucrase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption syndrome hypersensitivity to guaifenesin,paracetamol, phenylephrine or other components of the drug.

With caution: deficiency of glucose-6-phosphate dehydrogenase, blood diseases, congenital hyperbilirubinemia (Gilbert, Dubin-Johnson, Rotor syndromes), hyperoxaluria, bronchial asthma, COPD, renal failure of mild to moderate severity, dehydration, hypovolemia, anorexia, bexia (insufficient supply of glutathione in the liver), viral hepatitis, alcoholic liver damage, alcoholism, Raynaud's syndrome

simultaneous use of cardiac glycosides, beta-blockers, methyldopa and other antihypertensive drugs, advanced age.

special instructions

It is recommended to take the drug in the shortest possible course and in the minimum effective dose necessary to eliminate symptoms.

Do not use the drug concurrently with other cough, cold remedies or drugs with decongestant action.

Simultaneous use of the drug with other paracetamol-containing drugs should be avoided, as this can cause an overdose of paracetamol.

In patients with alcoholic liver disease, the negative consequences of an overdose are more pronounced.

When using the drug for more than 5 days, the peripheral blood parameters and the functional state of the liver should be monitored.

The drug distorts the results of laboratory tests of glucose and uric acid in the blood plasma.

It is recommended to take a sufficient amount of fluids during treatment.

Possibly pink urine.

Guaifenesin, which is part of the drug, can give false positive results in the determination of 5-hydroxyindoleacetic and vanillin mandelic acids in urine due to the effect of guaifenesin metabolites on color (guaifenesin should be discontinued 48 hours before urine collection for these tests).

The preparation contains sodium, which should be taken into account by patients on a diet with low sodium intake.

The drug contains aspartame, which is a source of phenylalanine, which can be toxic to patients with phenylketonuria.

During the use of the drug, you must refrain from taking alcohol and medications containing ethanol.

Influence on the ability to drive vehicles and use mechanisms

When driving vehicles and engaging in other potentially hazardous activities, it is necessary to take into account that the drug can cause side effects such as dizziness and confusion.

Structure

1 sachet

paracetamol 500 mg

guaifenesin 200 mg

phenylephrine hydrochloride 10 mg

Excipients: sucrose - 2000 mg, citric acid - 330 mg, tartaric acid - 330 mg, sodium cyclamate - 200 mg, sodium citrate - 500 mg, aspartame - 6 mg, ascorbic acid - 100 mg, potassium acesulfame - 17 mg, flavor lemon 8476 - 50 mg, lemon juice flavor - 120 mg, menthol flavor - 100 mg, quinoline yellow dye - 1 mg.

Method of administration and dosage

Adults and children over 12 years old: 1 sachet.

If necessary, repeat the intake every 4-6 hours, but not more than 4 doses (sachets) per day.

The maximum daily dose is 4 sachets.

The maximum duration of using the drug without consulting a doctor is no more than 5 days.

Dissolve the contents of one sachet in hot, but not boiling water (250 ml).

Allow to cool to an acceptable temperature.

Drink up.

Side effects

The incidence of adverse reactions is estimated as follows: very often (? 1/10), often (from? 1/100 to < 1/10), infrequently (from? 1/1000 to < 1/100), rarely (from? 1 / 10,000 to < 1/1000), very rare (< 1/10,000), frequency unknown (cannot be estimated from available data).

Paracetamol

Allergic reactions: rarely - urticaria, anaphylaxis, bronchospasm, angioedema.

Skin and subcutaneous tissue disorders: rarely - skin rash, frequency unknown - Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), acute generalized exanthematous pustulosis.

From the nervous system: rarely - dizziness.

From the side of the organ of vision: rarely - accommodation paresis, increased intraocular pressure, mydriasis.

From the hematopoietic system: rarely - aplastic anemia, methemoglobinemia

very rarely - pathological changes in the blood, such as thrombocytopenia, agranulocytosis, hemolytic anemia, neutropenia, leukopenia, pancytopenia.

From the side of the cardiovascular system: rarely - increased blood pressure.

From the digestive system: rarely - nausea, vomiting, dry mouth, hepatotoxic effect.

From the urinary system: rarely - urinary retention, nephrotoxicity (papillary necrosis)

frequency unknown - interstitial nephritis.

Phenylephrine

From the side of the cardiovascular system: rarely - tachycardia, arterial hypertension, accompanied by headache, vomiting and heart palpitations.

From the nervous system: rarely - insomnia, nervousness, tremors, anxiety, agitation, confusion, irritability and headache.

From the digestive system: often - anorexia, nausea and vomiting.

Allergic reactions: rarely - skin rash, urticaria, anaphylaxis and bronchospasm.

Guaifenesin

From the nervous system: rarely - headache, dizziness and drowsiness.

From the digestive system: rarely - gastrointestinal discomfort, nausea, vomiting and diarrhea.

Drug interactions

Paracetamol

Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, flumecinol, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites, which makes it possible to develop severe intoxication with a slight overdose.

Long-term use of barbiturates reduces the effectiveness of paracetamol.

Concomitant use with ethanol increases the risk of acute pancreatitis.

Inhibitors of microsomal oxidation (including cimetidine) reduce the risk of hepatotoxic effects.

When used together with NSAIDs, incl.

salicylates, the nephrotoxic effect of paracetamol increases.

Diflunisal increases the plasma concentration of paracetamol by 50%, which increases the risk of developing hepatotoxicity.

Metoclopramide and domperidone may increase the rate of absorption of paracetamol.

Cholestyramine may reduce the rate of absorption of paracetamol.

Isoniazid reduces the clearance of paracetamol by suppressing its metabolic transformation in the liver, which can lead to an increase in the pharmacological effects of paracetamol and / or its toxicity.

Probenecid causes a decrease in the clearance of paracetamol by almost 2 times due to inhibition of the conjugation of paracetamol with glucuronic acid.

When used simultaneously with probenecid, a reduction in the dose of paracetamol should be considered.

Regular use of paracetamol can lead to a possible decrease in zidovudine metabolism (increased risk of neutropenia).

Paracetamol can reduce the bioavailability of lamotrigine with a possible decrease in the severity of its effect due to the possible induction of metabolic transformation of lamotrigine in the liver.

Paracetamol enhances the effect of indirect anticoagulants, which increases the risk of bleeding and reduces the activity of uricosuric drugs.

Phenylephrine

Reduces the hypotensive effect of diuretics and antihypertensive drugs (including methyldopa, mecamylamine, guanadrel, guanethidine).

Phenothiazines, alpha-blockers (phentolamine), furosemide and other diuretics reduce the hypertensive effect.

MAO inhibitors (including furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulants increase the pressor effect and arrhythmogenicity of phenylephrine.

Beta-blockers reduce the cardiac stimulating activity, arterial hypertension is possible against the background of reserpine (due to the depletion of catecholamines in the adrenergic endings, the sensitivity to adrenergic agonists increases).

Inhalation anesthetics (including chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias, since they sharply increase myocardial sensitivity to sympathomimetics.

Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect.

Reduces the antianginal effect of nitrates, which in turn can reduce the pressor effect of sympathomimetics and the risk of arterial hypotension (simultaneous use is allowed depending on the achievement of the desired therapeutic effect).

Thyroid hormones increase (mutually) the effect and the associated risk of coronary insufficiency (especially in coronary atherosclerosis).

The simultaneous use of phenylephrine and other sympathomimetic amines can lead to an increase in blood pressure and other side effects from the cardiovascular system.

Concomitant use of cardiac glycosides (eg, digoxin) and phenylephrine may increase the risk of arrhythmias and myocardial infarction.

Guaifenesin

Codeine makes it difficult for the liquefied sputum to pass.

Compatible with bronchodilators, antimicrobial drugs, cardiac glycosides.

Storage conditions

Store at a temperature of 15-25 С out of the reach of children.

Active substance

Paracetamol, Phenylephrine

Dosage

200mg + 500mg + 10mg x 4.36g

Structure

1 sachet paracetamol 500 mg guaifenesin 200 mg phenylephrine hydrochloride 10 mg Excipients: sucrose - 2000 mg, citric acid - 330 mg, tartaric acid - 330 mg, sodium cyclamate - 200 mg, sodium citrate - 500 mg, aspartame - 6 mg, ascorbic acid 100 mg, potassium acesulfame 17 mg, lemon flavor 8476 - 50 mg, lemon juice flavor - 120 mg, menthol flavor - 100 mg, quinoline yellow dye - 1 mg.

INN / Active ingredient

paracetamol, guaifenesin, phenylephrine hydrochloride

Storage conditions and periods

At a temperature not higher than 25 degrees.

Specifications